Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Acute Myeloid Leukemia with Myelodisplasia-Related Changes (AML-MRC) Defined Only By Morphological Findings May Not Represent a Poor Prognosis AML

Blood (2019) 134 (Supplement_1): 2612.

https://doi.org/10.1182/blood-2019-129153

Published: 2019

Journal Articles

Impact of Red Blood Cell Transfusion Burden Status in Patients with Lower-Risk Myelodysplastic Syndromes

Montserrat Arnan Sangerman, Helena Pomares, MD PhD, Esther Alonso, MD, Javier Grau, MD PhD, Mercedes Galiano, Maite Encuentra, Anna Sureda, MD PhD

Blood (2019) 134 (Supplement_1): 3013.

https://doi.org/10.1182/blood-2019-127486

Published: 2019

Journal Articles

Validation of Low Risk Prognostic Scoring System (LR-PSS) in Patients with Lower Risk IPSS-R Myelodysplastic Syndrome. Results from a Single Center

Montserrat Arnan Sangerman, MD PhD, Helena Pomares, MD PhD, Esther Alonso, MD, Mercedes Galiano, Maite Encuentra, Javier Grau, MD PhD, Anna Sureda, MD PhD

Blood (2019) 134 (Supplement_1): 4270.

https://doi.org/10.1182/blood-2019-127901

Published: 2019

Journal Articles

Invasive Fungal Infections in Patients with High-Risk MDS and AML Treated with Azacitidine

Helena Pomares, MD, Montserrat Arnan, MD PhD, Isabel Sánchez-Ortega, MD PhD, Anna Sureda, MD PhD, Rafael F. Duarte, MD PhD

Blood (2015) 126 (23): 5251.

https://doi.org/10.1182/blood.V126.23.5251.5251

Published: 2015

Journal Articles

Prevalence, Predictive Factors Therapy and Outcome of Patients with Follicular Lymphoma Refractory to First Line Immunochemotherapy

Marc Sorigue, MD, Juan-Manuel Sancho, Santiago Mercadal, MD, Ruben Fernández-Álvarez, MD, Helena Pomares, MD, Olga Garcia, Eva González-Barca, MD PhD, Esther González-García, MD, Miriam Moreno, MD, Cristina Motlló, MD, Montserrat García, MD, Jose-Tomas Navarro, MD PhD, Eva domingo-Domenech, MD, Evarist Feliu, MD PhD, Anna Sureda, MD PhD, Josep-Maria Ribera, MD PhD

Blood (2015) 126 (23): 1510.

https://doi.org/10.1182/blood.V126.23.1510.1510

Published: 2015

Journal Articles

Molecular Genetic Profiling in Chronic Myelomonocytic Leukemia with Low Risk Cytogenetic Features

Laura Palomo, MSc, Blanca Xicoy, MD PhD, Montse Arnan, MD, Marta Cabezon, Rosa Coll, MD, Vera Ademà, MSc, Francisco Fuster, MSc, Javier Grau, MD, María José Jiménez, Helena Pomares, MD, Sílvia Marcé, PhD, Maria Pilar Armengol, PhD, Mar Mallo, PhD, Fuensanta Millá, MD PhD, Evarist Feliu, MD PhD, Francesc Sole, PhD, Lurdes Zamora, PhD

Blood (2015) 126 (23): 2883.

https://doi.org/10.1182/blood.V126.23.2883.2883

Published: 2015

Journal Articles

A Score Based on IPSS-R, Ferritin and EPO Levels Predicts Erythroid Response to ESAs and Survival in Lower Risk Anemic MDS Patients with High Probability of Response to ESAs: Spresas Sub-Analysis from the GESMD

María Díez Campelo, MD PhD, Julio Davila, MD, Sanchez Barba Mercedes, MD, Maria Lopez-Pavia, MD, Esperanza Such, PhD, Teresa Bernal, MD, Elisa Luño, Fernando Ramos, Marisa Calabuig, MD, Helena Pomares, MD, Bernardo Gonzalez, Brayan Merchan, MD, Edgardo Barranco, MD, Reyes Sancho Tello, Marta Callejas, Maria Jose Requena, María José Jiménez, Maria Pedreño, Angeles Medina, MD, Ana I Vicente, PhD, Andrea Campeny, Montse Cortes Sansa, Carmen Pedro, MD, Jose Falantes, MD, Maria Jesus Arilla, Abelardo Bárez, MD, Regina Garcia, MD, Maria Jose Arcos, Valle Gomez, Carolina Muñoz, Carlos Cervero, MD, Javier Casaño, Raquel De Paz, Luz Amigo, Andres Insunza, Juan Antonio Muñoz, Maria Teresa Cedena, Marta Gomez, Patricia Font, Raquel Del Campo, Carlos Fernandez Lago, Jose Antonio Gonzalez Hurtado, Maria Dolores Linares Latorre, Asuncion Mora Casado, Maria Vahi, MD PhD, Luis Benlloch, Guillermo Sanz, MD PhD, María Consuelo Cañizo, MD PhD

Blood (2015) 126 (23): 2896.

https://doi.org/10.1182/blood.V126.23.2896.2896

Published: 2015

Journal Articles

Validation of the Low Risk Prognostic Scoring System (LR-PSS) in Patients with VERY Low, Low and Intermediate Risk IPSS-R Myelodysplastic Syndrome. Results from a Single Center

Helena Pomares, MD, Isabel Sánchez-Ortega, MD PhD, Esther Alonso, MD, Javier Grau, MD, Rafael F. Duarte, MD PhD, Anna Sureda, MD PhD, Montserrat Arnan, MD PhD

Blood (2015) 126 (23): 2902.

https://doi.org/10.1182/blood.V126.23.2902.2902

Published: 2015

Journal Articles

Disease-Attributable Mortality in the Myelodysplastic Syndromes (MDS): A Study from the Spanish MDS Cooperative Group (GESMD)

Blood (2015) 126 (23): 1672.

https://doi.org/10.1182/blood.V126.23.1672.1672

Published: 2015

Journal Articles

How Are Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS) Treated? Impact on Clinical Evolution and Overall Survival: A Report from the Erasme Study

Julia Montoro, MD, Helena Pomares, MD, Itziar Oiartzabal, MD, Teresa Bernal, MD, Edgardo Barranco, MD, Rosa Coll, MD, Rafael Romero, MD, Marisa Calabuig, MD, Eduardo Salido, MD PhD, Marta Castellanos, MD, Angeles Medina, MD, Gemma Azaceta, MD PhD, Mireya Navarro, MD, Silvia López, David Valcárcel, MD PhD

Blood (2015) 126 (23): 5239.

https://doi.org/10.1182/blood.V126.23.5239.5239

Published: 2015

Journal Articles

Primary Cutaneous Marginal Zone B-Cell Lymphoma Treated with Intralesional Rituximab: Experience of a Single Center

Eva Domingo-Domenech, MD, Queralt Salas, MD, Fina Climent, MD PhD, Carmen Aguilera, Mrs, Helena Pomares, MD, Eva González-Barca, MD PhD, Santiago Mercadal, MD, Anna Lucas, MD, Alberto Fernandez de Sevilla, MD PhD, Anna Sureda, MD PhD, Octavio Servitje, MD PhD

Blood (2015) 126 (23): 5087.

https://doi.org/10.1182/blood.V126.23.5087.5087

Published: 2015

Journal Articles

Utility of SNP Arrays in Chronic Myelomonocytic Leukemia with Low Risk Cytogenetic Features or No Metaphases

Blood (2014) 124 (21): 4659.

https://doi.org/10.1182/blood.V124.21.4659.4659

Published: 2014

NARROW

Acute Myeloid Leukemia with Myelodisplasia-Related Changes (AML-MRC) Defined Only By Morphological Findings May Not Represent a Poor Prognosis AML

Impact of Red Blood Cell Transfusion Burden Status in Patients with Lower-Risk Myelodysplastic Syndromes

Validation of Low Risk Prognostic Scoring System (LR-PSS) in Patients with Lower Risk IPSS-R Myelodysplastic Syndrome. Results from a Single Center

Invasive Fungal Infections in Patients with High-Risk MDS and AML Treated with Azacitidine

Prevalence, Predictive Factors Therapy and Outcome of Patients with Follicular Lymphoma Refractory to First Line Immunochemotherapy

Molecular Genetic Profiling in Chronic Myelomonocytic Leukemia with Low Risk Cytogenetic Features

A Score Based on IPSS-R, Ferritin and EPO Levels Predicts Erythroid Response to ESAs and Survival in Lower Risk Anemic MDS Patients with High Probability of Response to ESAs: Spresas Sub-Analysis from the GESMD

Validation of the Low Risk Prognostic Scoring System (LR-PSS) in Patients with VERY Low, Low and Intermediate Risk IPSS-R Myelodysplastic Syndrome. Results from a Single Center

Disease-Attributable Mortality in the Myelodysplastic Syndromes (MDS): A Study from the Spanish MDS Cooperative Group (GESMD)

How Are Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS) Treated? Impact on Clinical Evolution and Overall Survival: A Report from the Erasme Study

Primary Cutaneous Marginal Zone B-Cell Lymphoma Treated with Intralesional Rituximab: Experience of a Single Center

Utility of SNP Arrays in Chronic Myelomonocytic Leukemia with Low Risk Cytogenetic Features or No Metaphases

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only